MicroRNA: Defining a new niche in Leukemia

Fernandes, Queenie

doi:10.1016/j.blre.2016.11.003

Cited by 17 publications

(12 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiRNAs are small regulatory ribonucleic acids that exert their function via a RNA-induced silencing complex (RISC) leading to a down regulation of targets by a sequence specific binding of the miRNA's seed region to a 3′UTR target sequence ( 12–14 ). Changes in miRNA expression and subsequently in their targeting are of special interest to understand the gene regulatory processes that are induced upon T cell activation ( 11 , 15 , 16 ). Furthermore, miRNAs may allow the manipulation of specific T cell properties in context of immunotherapies and cancer treatment ( 17 ).…”

Section: Introductionmentioning

confidence: 99%

Quantitative and time-resolved miRNA pattern of early human T cell activation

Diener

Hart

Kehl

et al. 2020

Nucleic Acids Research

View full text Add to dashboard Cite

T cells are central to the immune response against various pathogens and cancer cells. Complex networks of transcriptional and post-transcriptional regulators, including microRNAs (miRNAs), coordinate the T cell activation process. Available miRNA datasets, however, do not sufficiently dissolve the dynamic changes of miRNA controlled networks upon T cell activation. Here, we established a quantitative and time-resolved expression pattern for the entire miRNome over a period of 24 h upon human T-cell activation. Based on our time-resolved datasets, we identified central miRNAs and specified common miRNA expression profiles. We found the most prominent quantitative expression changes for miR-155-5p with a range from initially 40 molecules/cell to 1600 molecules/cell upon T-cell activation. We established a comprehensive dynamic regulatory network of both the up- and downstream regulation of miR-155. Upstream, we highlight IRF4 and its complexes with SPI1 and BATF as central for the transcriptional regulation of miR-155. Downstream of miR-155-5p, we verified 17 of its target genes by the time-resolved data recorded after T cell activation. Our data provide comprehensive insights into the range of stimulus induced miRNA abundance changes and lay the ground to identify efficient points of intervention for modifying the T cell response.

show abstract

Section: Introductionmentioning

confidence: 99%

Quantitative and time-resolved miRNA pattern of early human T cell activation

Diener

Hart

Kehl

et al. 2020

Nucleic Acids Research

View full text Add to dashboard Cite

show abstract

“…Notable examples of these miRNAs are given by miR-155, miR-29, miR-150 and miR-196b [ 15 ]. Recently, a few studies demonstrated miR-362-5p could act as tumor suppressors by targeting phosphatidylinositol 3-kinase-C2beta and inhibiting proliferation and migration of neuroblastoma cells [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia

Wang

Yang

et al. 2018

J Transl Med

View full text Add to dashboard Cite

BackgroundMicroRNAs are of special interest in cancer research and hold significant promise as diagnostic and prognostic biomarkers for malignant disease. MiR-362-5p have been found to exert both oncogenic and tumor suppressive effects depending highly on the cellular context. The aim of this study was to determine whether the expression of miR-362-5p can be served as a prognostic factor for patients with cytogentically normal acute myeloid leukemia (CN-AML).MethodsWe enrolled 224 patients with CN-AML and measured the expression of miR-362-5p by quantitative real time PCR analysis. We classified patients into high and low expression based on the median value. The Cox regression analyses were carried out to assess the prognostic significance of miR-362-5p expression in the context of the well-established predictors. Additionally, microRNA expression profiling were conducted to identify the biological insights between high and low group.ResultsHigh expressers had older age. High expressers obtained shorter overall survival in the univariate analysis. The independent prognostic value of miR-362-5p remained in the context of the well-established clinical and cytogenetic predictors. Moreover, the prognostic value of miR-362-5p was also validated in an independent cohort of CN-AML. Notably, numerous oncomiRs were also high expressed in high miR-362-5p group.ConclusionHigh miR-362-5p expression was associated with poorer overall survival implicating the oncogenic function in AML development.

show abstract

“…Epstein–Barr virus is known to encode for around 44 miRNAs ( 80 ). miRNAs are short non-coding RNAs that act at the post-transcriptional level and are often linked to oncogenic pathogenesis ( 81 ). BART miRNA expression is a characteristic of EBV infection in almost all cell types.…”

Section: Ebv Protein Expressionmentioning

confidence: 99%

Role of Epstein–Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target

et al. 2018

Self Cite

View full text Add to dashboard Cite

The role of Epstein–Barr virus (EBV) infection in the development and progression of tumor cells has been described in various cancers. Etiologically, EBV is a causative agent in certain variants of head and neck cancers such as nasopharyngeal cancer. Proteins expressed by the EVB genome are involved in invoking and perpetuating the oncogenic properties of the virus. However, these protein products were also identified as important targets for therapeutic research in the past decades, particularly within the context of immunotherapy. The adoptive transfer of EBV-targeted T-cells as well as the development of EBV vaccines has opened newer lines of research to conceptualize novel therapeutic approaches toward the disease. This review addresses the most important aspects of the association of EBV with head and neck cancers from an immunological perspective. It also aims to highlight the current and future prospects of enhanced EBV-targeted immunotherapies.

show abstract

MicroRNA: Defining a new niche in Leukemia

Cited by 17 publications

References 124 publications

Quantitative and time-resolved miRNA pattern of early human T cell activation

Quantitative and time-resolved miRNA pattern of early human T cell activation

MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia

Role of Epstein–Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target

Contact Info

Product

Resources

About